Moreover, genomic homozygosity is linked with a worse prognosis in lung cancer patients treated with single-agent immunotherapy, so HLA-I typing could become a non-invasive and cost-effective biomarker to guide treatment personalization, as patients with HLA-I homozygosity are less likely to experience clinical benefit from single-agent anti-PD1/PDL1 therapy. The gene discussed is CD274; the disease is lung cancer.